ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Genetic Obesity Drug Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-21G10795
Home | Market Reports | Health| Health Conditions| Obesity
Global Genetic Obesity Drug Market Research Report 2022
BUY CHAPTERS

Global Genetic Obesity Drug Market Research Report 2025

Code: QYRE-Auto-21G10795
Report
January 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Sanofi
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon Ltd.
Adocia
GlaxoSmithKline PLC
Novo Nordisk A S
Oramed Pharmaceuticals Inc.
WOCKHARDT
Eli Lilly and Company
Merck& Co. Inc
Julphar
Bristol Myers Squibb Company

Genetic Obesity Drug Market Size

The global market for Genetic Obesity Drug was valued at US$ 2966 million in the year 2024 and is projected to reach a revised size of US$ 4611 million by 2031, growing at a CAGR of 6.6% during the forecast period.

Genetic Obesity Drug Market

Genetic Obesity Drug Market

Obesity, a condition in which body fat levels are elevated to extreme extent, is a common disorder. Obesity is a condition caused by the lower levels of the metabolism rate.The current advancement in Genetic Obesity Drugs in rapidly recovering the appetite inhibiting hormone level in the body is anticipated to increase the adoption of Genetic obesity drugs in physicians.
The global genetic obesity drug market refers to the market for medications and therapies used to treat obesity caused by genetic factors. Genetic obesity is a complex condition that arises from various genetic mutations and alterations, leading to an increased risk of excessive weight gain and difficulty in losing weight.
The treatment of genetic obesity focuses on managing weight gain and associated health issues. While lifestyle modifications such as diet and exercise are important in managing obesity, genetic obesity may require additional targeted interventions. Currently, there is ongoing research and development in the field of genetic obesity drugs, with the aim of developing medications that can directly address the underlying genetic causes of obesity.
The global genetic obesity drug market is influenced by factors such as the increasing prevalence of obesity, advancements in genetic research, and the need for personalized treatment options. However, it’s important to note that the market for genetic obesity drugs is still in its early stages, and there are currently limited approved medications specifically targeted towards genetic obesity.
Geographically, the market for genetic obesity drugs is expected to witness growth across regions with a high prevalence of obesity, such as North America, Europe, and the Asia Pacific. These regions have well-established healthcare infrastructure and research capabilities, which contribute to advancements in genetic obesity treatment options.
Key players in the global genetic obesity drug market include pharmaceutical companies, biotechnology firms, and research institutions. These entities are actively involved in research and development efforts to identify novel drug targets, explore gene-based therapies, and conduct clinical trials.
It’s important to note that the development and approval of drugs for genetic obesity are complex processes that involve rigorous testing, regulatory approvals, and extensive research. The timeline for the availability of specific genetic obesity drugs may vary based on the stage of development and regulatory requirements.
In summary, the global genetic obesity drug market is in its early stages of development. Although there are currently limited approved medications targeted towards genetic obesity, ongoing research and advancements in genetic understanding hold promise for the future. As research progresses and personalized treatment approaches emerge, the market for genetic obesity drugs may expand, offering new treatment options for individuals affected by genetic forms of obesity.
This report aims to provide a comprehensive presentation of the global market for Genetic Obesity Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genetic Obesity Drug.
The Genetic Obesity Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Genetic Obesity Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Genetic Obesity Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Genetic Obesity Drug Market Report

Report Metric Details
Report Name Genetic Obesity Drug Market
Accounted market size in year US$ 2966 million
Forecasted market size in 2031 US$ 4611 million
CAGR 6.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Sibutramine
  • Orlistat
  • Sympathomimetic Drugs
  • Receptors Antagonists
  • Others
Segment by Application
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., Adocia, GlaxoSmithKline Plc., Novo Nordisk A/S., Oramed Pharmaceuticals, Inc, Wockhardt., Eli Lilly and Company., Merck & Co., Inc., Julphar., Bristol-Myers Squibb Company.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Genetic Obesity Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Genetic Obesity Drug Market growing?

Ans: The Genetic Obesity Drug Market witnessing a CAGR of 6.6% during the forecast period 2025-2031.

What is the Genetic Obesity Drug Market size in 2031?

Ans: The Genetic Obesity Drug Market size in 2031 will be US$ 4611 million.

Who are the main players in the Genetic Obesity Drug Market report?

Ans: The main players in the Genetic Obesity Drug Market are Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., Adocia, GlaxoSmithKline Plc., Novo Nordisk A/S., Oramed Pharmaceuticals, Inc, Wockhardt., Eli Lilly and Company., Merck & Co., Inc., Julphar., Bristol-Myers Squibb Company.

What are the Application segmentation covered in the Genetic Obesity Drug Market report?

Ans: The Applications covered in the Genetic Obesity Drug Market report are Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy, Others

What are the Type segmentation covered in the Genetic Obesity Drug Market report?

Ans: The Types covered in the Genetic Obesity Drug Market report are Sibutramine, Orlistat, Sympathomimetic Drugs, Receptors Antagonists, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Genetic Obesity Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Sibutramine
1.2.3 Orlistat
1.2.4 Sympathomimetic Drugs
1.2.5 Receptors Antagonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Genetic Obesity Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Genetic Obesity Drug Market Perspective (2020-2031)
2.2 Global Genetic Obesity Drug Growth Trends by Region
2.2.1 Global Genetic Obesity Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Genetic Obesity Drug Historic Market Size by Region (2020-2025)
2.2.3 Genetic Obesity Drug Forecasted Market Size by Region (2026-2031)
2.3 Genetic Obesity Drug Market Dynamics
2.3.1 Genetic Obesity Drug Industry Trends
2.3.2 Genetic Obesity Drug Market Drivers
2.3.3 Genetic Obesity Drug Market Challenges
2.3.4 Genetic Obesity Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Genetic Obesity Drug Players by Revenue
3.1.1 Global Top Genetic Obesity Drug Players by Revenue (2020-2025)
3.1.2 Global Genetic Obesity Drug Revenue Market Share by Players (2020-2025)
3.2 Global Genetic Obesity Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Genetic Obesity Drug Revenue
3.4 Global Genetic Obesity Drug Market Concentration Ratio
3.4.1 Global Genetic Obesity Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Genetic Obesity Drug Revenue in 2024
3.5 Global Key Players of Genetic Obesity Drug Head office and Area Served
3.6 Global Key Players of Genetic Obesity Drug, Product and Application
3.7 Global Key Players of Genetic Obesity Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Genetic Obesity Drug Breakdown Data by Type
4.1 Global Genetic Obesity Drug Historic Market Size by Type (2020-2025)
4.2 Global Genetic Obesity Drug Forecasted Market Size by Type (2026-2031)
5 Genetic Obesity Drug Breakdown Data by Application
5.1 Global Genetic Obesity Drug Historic Market Size by Application (2020-2025)
5.2 Global Genetic Obesity Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Genetic Obesity Drug Market Size (2020-2031)
6.2 North America Genetic Obesity Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Genetic Obesity Drug Market Size by Country (2020-2025)
6.4 North America Genetic Obesity Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Genetic Obesity Drug Market Size (2020-2031)
7.2 Europe Genetic Obesity Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Genetic Obesity Drug Market Size by Country (2020-2025)
7.4 Europe Genetic Obesity Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Genetic Obesity Drug Market Size (2020-2031)
8.2 Asia-Pacific Genetic Obesity Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Genetic Obesity Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Genetic Obesity Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Genetic Obesity Drug Market Size (2020-2031)
9.2 Latin America Genetic Obesity Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Genetic Obesity Drug Market Size by Country (2020-2025)
9.4 Latin America Genetic Obesity Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Genetic Obesity Drug Market Size (2020-2031)
10.2 Middle East & Africa Genetic Obesity Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Genetic Obesity Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Genetic Obesity Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Details
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Genetic Obesity Drug Introduction
11.1.4 Pfizer, Inc. Revenue in Genetic Obesity Drug Business (2020-2025)
11.1.5 Pfizer, Inc. Recent Development
11.2 Sanofi.
11.2.1 Sanofi. Company Details
11.2.2 Sanofi. Business Overview
11.2.3 Sanofi. Genetic Obesity Drug Introduction
11.2.4 Sanofi. Revenue in Genetic Obesity Drug Business (2020-2025)
11.2.5 Sanofi. Recent Development
11.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
11.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Company Details
11.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Business Overview
11.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Introduction
11.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue in Genetic Obesity Drug Business (2020-2025)
11.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Development
11.4 Biocon.
11.4.1 Biocon. Company Details
11.4.2 Biocon. Business Overview
11.4.3 Biocon. Genetic Obesity Drug Introduction
11.4.4 Biocon. Revenue in Genetic Obesity Drug Business (2020-2025)
11.4.5 Biocon. Recent Development
11.5 Adocia
11.5.1 Adocia Company Details
11.5.2 Adocia Business Overview
11.5.3 Adocia Genetic Obesity Drug Introduction
11.5.4 Adocia Revenue in Genetic Obesity Drug Business (2020-2025)
11.5.5 Adocia Recent Development
11.6 GlaxoSmithKline Plc.
11.6.1 GlaxoSmithKline Plc. Company Details
11.6.2 GlaxoSmithKline Plc. Business Overview
11.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Introduction
11.6.4 GlaxoSmithKline Plc. Revenue in Genetic Obesity Drug Business (2020-2025)
11.6.5 GlaxoSmithKline Plc. Recent Development
11.7 Novo Nordisk A/S.
11.7.1 Novo Nordisk A/S. Company Details
11.7.2 Novo Nordisk A/S. Business Overview
11.7.3 Novo Nordisk A/S. Genetic Obesity Drug Introduction
11.7.4 Novo Nordisk A/S. Revenue in Genetic Obesity Drug Business (2020-2025)
11.7.5 Novo Nordisk A/S. Recent Development
11.8 Oramed Pharmaceuticals, Inc
11.8.1 Oramed Pharmaceuticals, Inc Company Details
11.8.2 Oramed Pharmaceuticals, Inc Business Overview
11.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Introduction
11.8.4 Oramed Pharmaceuticals, Inc Revenue in Genetic Obesity Drug Business (2020-2025)
11.8.5 Oramed Pharmaceuticals, Inc Recent Development
11.9 Wockhardt.
11.9.1 Wockhardt. Company Details
11.9.2 Wockhardt. Business Overview
11.9.3 Wockhardt. Genetic Obesity Drug Introduction
11.9.4 Wockhardt. Revenue in Genetic Obesity Drug Business (2020-2025)
11.9.5 Wockhardt. Recent Development
11.10 Eli Lilly and Company.
11.10.1 Eli Lilly and Company. Company Details
11.10.2 Eli Lilly and Company. Business Overview
11.10.3 Eli Lilly and Company. Genetic Obesity Drug Introduction
11.10.4 Eli Lilly and Company. Revenue in Genetic Obesity Drug Business (2020-2025)
11.10.5 Eli Lilly and Company. Recent Development
11.11 Merck & Co., Inc.
11.11.1 Merck & Co., Inc. Company Details
11.11.2 Merck & Co., Inc. Business Overview
11.11.3 Merck & Co., Inc. Genetic Obesity Drug Introduction
11.11.4 Merck & Co., Inc. Revenue in Genetic Obesity Drug Business (2020-2025)
11.11.5 Merck & Co., Inc. Recent Development
11.12 Julphar.
11.12.1 Julphar. Company Details
11.12.2 Julphar. Business Overview
11.12.3 Julphar. Genetic Obesity Drug Introduction
11.12.4 Julphar. Revenue in Genetic Obesity Drug Business (2020-2025)
11.12.5 Julphar. Recent Development
11.13 Bristol-Myers Squibb Company.
11.13.1 Bristol-Myers Squibb Company. Company Details
11.13.2 Bristol-Myers Squibb Company. Business Overview
11.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Introduction
11.13.4 Bristol-Myers Squibb Company. Revenue in Genetic Obesity Drug Business (2020-2025)
11.13.5 Bristol-Myers Squibb Company. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Sanofi
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon Ltd.
Adocia
GlaxoSmithKline PLC
Novo Nordisk A S
Oramed Pharmaceuticals Inc.
WOCKHARDT
Eli Lilly and Company
Merck& Co. Inc
Julphar
Bristol Myers Squibb Company
List of Tables
 Table 1. Global Genetic Obesity Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Sibutramine
 Table 3. Key Players of Orlistat
 Table 4. Key Players of Sympathomimetic Drugs
 Table 5. Key Players of Receptors Antagonists
 Table 6. Key Players of Others
 Table 7. Global Genetic Obesity Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Genetic Obesity Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Genetic Obesity Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Genetic Obesity Drug Market Share by Region (2020-2025)
 Table 11. Global Genetic Obesity Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Genetic Obesity Drug Market Share by Region (2026-2031)
 Table 13. Genetic Obesity Drug Market Trends
 Table 14. Genetic Obesity Drug Market Drivers
 Table 15. Genetic Obesity Drug Market Challenges
 Table 16. Genetic Obesity Drug Market Restraints
 Table 17. Global Genetic Obesity Drug Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Genetic Obesity Drug Market Share by Players (2020-2025)
 Table 19. Global Top Genetic Obesity Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Obesity Drug as of 2024)
 Table 20. Ranking of Global Top Genetic Obesity Drug Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Genetic Obesity Drug Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Genetic Obesity Drug, Headquarters and Area Served
 Table 23. Global Key Players of Genetic Obesity Drug, Product and Application
 Table 24. Global Key Players of Genetic Obesity Drug, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Genetic Obesity Drug Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Genetic Obesity Drug Revenue Market Share by Type (2020-2025)
 Table 28. Global Genetic Obesity Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Genetic Obesity Drug Revenue Market Share by Type (2026-2031)
 Table 30. Global Genetic Obesity Drug Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Genetic Obesity Drug Revenue Market Share by Application (2020-2025)
 Table 32. Global Genetic Obesity Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Genetic Obesity Drug Revenue Market Share by Application (2026-2031)
 Table 34. North America Genetic Obesity Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Genetic Obesity Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Genetic Obesity Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Genetic Obesity Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Genetic Obesity Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Genetic Obesity Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Genetic Obesity Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Genetic Obesity Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Genetic Obesity Drug Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Genetic Obesity Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Genetic Obesity Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Genetic Obesity Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Genetic Obesity Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Genetic Obesity Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Genetic Obesity Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Pfizer, Inc. Company Details
 Table 50. Pfizer, Inc. Business Overview
 Table 51. Pfizer, Inc. Genetic Obesity Drug Product
 Table 52. Pfizer, Inc. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 53. Pfizer, Inc. Recent Development
 Table 54. Sanofi. Company Details
 Table 55. Sanofi. Business Overview
 Table 56. Sanofi. Genetic Obesity Drug Product
 Table 57. Sanofi. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 58. Sanofi. Recent Development
 Table 59. Tonghua Dongbao Pharmaceutical Co., Ltd. Company Details
 Table 60. Tonghua Dongbao Pharmaceutical Co., Ltd. Business Overview
 Table 61. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product
 Table 62. Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 63. Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Development
 Table 64. Biocon. Company Details
 Table 65. Biocon. Business Overview
 Table 66. Biocon. Genetic Obesity Drug Product
 Table 67. Biocon. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 68. Biocon. Recent Development
 Table 69. Adocia Company Details
 Table 70. Adocia Business Overview
 Table 71. Adocia Genetic Obesity Drug Product
 Table 72. Adocia Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 73. Adocia Recent Development
 Table 74. GlaxoSmithKline Plc. Company Details
 Table 75. GlaxoSmithKline Plc. Business Overview
 Table 76. GlaxoSmithKline Plc. Genetic Obesity Drug Product
 Table 77. GlaxoSmithKline Plc. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 78. GlaxoSmithKline Plc. Recent Development
 Table 79. Novo Nordisk A/S. Company Details
 Table 80. Novo Nordisk A/S. Business Overview
 Table 81. Novo Nordisk A/S. Genetic Obesity Drug Product
 Table 82. Novo Nordisk A/S. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 83. Novo Nordisk A/S. Recent Development
 Table 84. Oramed Pharmaceuticals, Inc Company Details
 Table 85. Oramed Pharmaceuticals, Inc Business Overview
 Table 86. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product
 Table 87. Oramed Pharmaceuticals, Inc Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 88. Oramed Pharmaceuticals, Inc Recent Development
 Table 89. Wockhardt. Company Details
 Table 90. Wockhardt. Business Overview
 Table 91. Wockhardt. Genetic Obesity Drug Product
 Table 92. Wockhardt. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 93. Wockhardt. Recent Development
 Table 94. Eli Lilly and Company. Company Details
 Table 95. Eli Lilly and Company. Business Overview
 Table 96. Eli Lilly and Company. Genetic Obesity Drug Product
 Table 97. Eli Lilly and Company. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 98. Eli Lilly and Company. Recent Development
 Table 99. Merck & Co., Inc. Company Details
 Table 100. Merck & Co., Inc. Business Overview
 Table 101. Merck & Co., Inc. Genetic Obesity Drug Product
 Table 102. Merck & Co., Inc. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 103. Merck & Co., Inc. Recent Development
 Table 104. Julphar. Company Details
 Table 105. Julphar. Business Overview
 Table 106. Julphar. Genetic Obesity Drug Product
 Table 107. Julphar. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 108. Julphar. Recent Development
 Table 109. Bristol-Myers Squibb Company. Company Details
 Table 110. Bristol-Myers Squibb Company. Business Overview
 Table 111. Bristol-Myers Squibb Company. Genetic Obesity Drug Product
 Table 112. Bristol-Myers Squibb Company. Revenue in Genetic Obesity Drug Business (2020-2025) & (US$ Million)
 Table 113. Bristol-Myers Squibb Company. Recent Development
 Table 114. Research Programs/Design for This Report
 Table 115. Key Data Information from Secondary Sources
 Table 116. Key Data Information from Primary Sources
 Table 117. Authors List of This Report


List of Figures
 Figure 1. Genetic Obesity Drug Picture
 Figure 2. Global Genetic Obesity Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Genetic Obesity Drug Market Share by Type: 2024 VS 2031
 Figure 4. Sibutramine Features
 Figure 5. Orlistat Features
 Figure 6. Sympathomimetic Drugs Features
 Figure 7. Receptors Antagonists Features
 Figure 8. Others Features
 Figure 9. Global Genetic Obesity Drug Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Genetic Obesity Drug Market Share by Application: 2024 VS 2031
 Figure 11. Hospitals Pharmacy Case Studies
 Figure 12. Retail Pharmacy Case Studies
 Figure 13. Online Pharmacy Case Studies
 Figure 14. Others Case Studies
 Figure 15. Genetic Obesity Drug Report Years Considered
 Figure 16. Global Genetic Obesity Drug Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 17. Global Genetic Obesity Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Genetic Obesity Drug Market Share by Region: 2024 VS 2031
 Figure 19. Global Genetic Obesity Drug Market Share by Players in 2024
 Figure 20. Global Top Genetic Obesity Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Obesity Drug as of 2024)
 Figure 21. The Top 10 and 5 Players Market Share by Genetic Obesity Drug Revenue in 2024
 Figure 22. North America Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. North America Genetic Obesity Drug Market Share by Country (2020-2031)
 Figure 24. United States Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Canada Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Europe Genetic Obesity Drug Market Share by Country (2020-2031)
 Figure 28. Germany Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. France Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. U.K. Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Italy Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Russia Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Nordic Countries Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Genetic Obesity Drug Market Share by Region (2020-2031)
 Figure 36. China Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Japan Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. South Korea Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. India Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Australia Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Latin America Genetic Obesity Drug Market Share by Country (2020-2031)
 Figure 44. Mexico Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Brazil Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East & Africa Genetic Obesity Drug Market Share by Country (2020-2031)
 Figure 48. Turkey Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. UAE Genetic Obesity Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Pfizer, Inc. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 52. Sanofi. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 53. Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 54. Biocon. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 55. Adocia Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 56. GlaxoSmithKline Plc. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 57. Novo Nordisk A/S. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 58. Oramed Pharmaceuticals, Inc Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 59. Wockhardt. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 60. Eli Lilly and Company. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 61. Merck & Co., Inc. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 62. Julphar. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 63. Bristol-Myers Squibb Company. Revenue Growth Rate in Genetic Obesity Drug Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Genetic Obesity Drug Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21G10795
Wed Jan 15 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Bariatric Surgery Implantable Devices - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-14E14688
Mon Dec 09 00:00:00 UTC 2024

$7900

Enterprise User

Add to Cart

Global Obesity Surgery Devices Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-0M7800
Wed Sep 25 00:00:00 UTC 2024

$9800

Enterprise User

Add to Cart

Obese Patient Stretcher Trolley - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-33U13823
Thu Sep 05 00:00:00 UTC 2024

$7900

Enterprise User

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions